**Core tip:** Hepatitis B is one of the most common infectious diseases worldwide. Despite advances in medicine, chronic hepatitis B virus (HBV) infection is currently incurable. In addition, clinical outcomes of kidney transplantation in HBV infected patients are still unclear. To further assess these outcomes, we conducted this systematic review and meta-analysis to assess patient and allograft outcomes after kidney transplantation in patients with HBV Infection. We found significant associations between HBV positive status and poor outcomes including 2.5-fold increased risk of mortality and 1.5-fold increased risk of allograft loss.

INTRODUCTION
============

Hepatitis B virus (HBV) infection is one of the most common infectious diseases and major health problems worldwide\[[@B1]-[@B3]\]. In 2017, approximately 257 million people have chronic hepatitis B virus infection\[[@B1]\]. Despite advances in medicine which have resulted in a cure for hepatitis C infection in recent years\[[@B4]\], chronic HBV infection is still currently considered as an incurable disease\[[@B2],[@B3],[@B5]\], leading to significant mortality (887000 death in 2015) and morbidities including cirrhosis and hepatocellular carcinoma\[[@B1],[@B2]\].

Advances in immunosuppression and kidney transplant techniques have led to significant improvements in short-term survival of the renal allograft\[[@B6]\]. Long-term graft survival, however, has remained relatively lagged behind and has now become one of the main problems in kidney transplantation\[[@B7]-[@B9]\]. Although HBV is preventable disease by HBV vaccine, HBV infection remains a challenge issue in patients with end-stage renal disease on dialysis, affecting from 1.3% up to 14.6% of chronic dialysis patients \[hepatitis B surface antigen (HBsAg) --positive\] depending on geographical regions\[[@B10]-[@B12]\], and, consequently leading to chronic HBV infection kidney transplant patients\[[@B13]-[@B31]\]. Among renal transplant patients with HBV (HBsAg positive), there have been reported cases of HBV reactivation\[[@B32]\], massive liver necrosis due to fulminant hepatitis, and severe cholestatic hepatitis after kidney transplantation\[[@B10],[@B16],[@B33]-[@B36]\]. In addition, chronic HBV infection may result in HBV-related membranous nephropathy after kidney transplantation\[[@B37]-[@B43]\].

Even though HBV is incurable, current more available antiviral agents against HBV effectively suppress viral replication\[[@B10]\]. Thus, these agents can prevent hepatic fibrosis\[[@B10]\] and potentially reduce significant hepatic and extra-hepatic complications related to chronic HBV. In spite of improvement of HBV care, outcomes of kidney transplantation including patient and allograft outcomes in recipients with HBV infection remain unclear. Thus, we conducted this meta-analysis to (1) Assess the risks of mortality and allograft failure in kidney transplant recipients with HBsAg-positive status; and (2) evaluate trends of patient's outcomes overtime.

MATERIALS AND METHODS
=====================

Literature review and search strategy
-------------------------------------

The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017080657). A systematic literature search of MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews from database inception to October 2017 was conducted to identify studies assessing outcomes of kidney transplantation including patient and allograft outcomes in patients with HBV. The systematic literature review was undertaken independently by two investigators (C.T. and W.C.) applying the search approach that incorporated the terms of "hepatitis B" or "HBV", or "viral hepatitis" and "kidney transplantation" which is provided in online supplementary data 1. No language limitation was applied. A manual search for conceivably relevant studies using references of the included articles was also performed. This study was conducted by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement\[[@B44]\] and previously published guidelines\[[@B45],[@B46]\].

Selection criteria
------------------

Eligible studies must be randomized controlled trials or observational studies including cohort studies, case-control, or cross-sectional that assessed the risks of mortality and/or allograft loss after kidney transplantation in patients with HBV (HBsAg-positive). They must provide the effect estimates odds ratios (OR), relative risks (RR), or hazard ratios (HR) with 95%CI. The comparison group consisted of HBsAg-negative kidney transplant recipients. Retrieved articles were individually reviewed for their eligibility by the two investigators (C.T. and W.C.) noted previously. Discrepancies were discussed and resolved by mutual consensus. Newcastle-Ottawa quality assessment scale was used to appraise the quality of study for case-control study and outcome of interest for cohort study\[[@B47]\]. The modified Newcastle-Ottawa scale was used for cross-sectional study\[[@B48]\], as shown in Table [1](#T1){ref-type="table"}.

###### 

Main characteristics of the studies assessing outcomes of kidney transplantation in patients with hepatitis B virus

  **Study**                     **Lee et al\[[@B55]\]**                    **Breitenfeldt et al\[[@B56]\]**   **Chan et al\[[@B21]\]**              **Morales et al\[[@B57]\]**                       **Ridruejo et al\[[@B52]\]**          **Aroldi et al\[[@B53]\]**            **Yap et al\[[@B18]\]**                 **Reddy et al\[[@B36]\]**                                                                                                                                                         **Grenha et al\[[@B31]\]**   **Lee et al\[[@B54]\]**
  ----------------------------- ------------------------------------------ ---------------------------------- ------------------------------------- ------------------------------------------------- ------------------------------------- ------------------------------------- --------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ----------------------------------------------------------------------------------------------------------------------
  Country                       Taiwan                                     Germany                            Hong Kong                             Spain                                             Argentina                             Italy                                 Hong Kong                               USA                                                                                                                                                                               Portugal                     Korea
  Study design                  Cohort study                               Cohort study                       Cohort study                          Cohort study                                      Cohort study                          Cohort study                          Cohort study                            Cohort                                                                                                                                                                            Cohort study                 Cohort study
  Year                          2001                                       2002                               2002                                  2004                                              2004                                  2005                                  2010                                    2011                                                                                                                                                                              2015                         2016
  Total number                  477                                        927                                509                                   3365                                              231                                   541                                   126                                     75681                                                                                                                                                                             2284                         3482
  Age (yr)                      38.6 ± 11.5                                41.7                               N/A                                   45.6 ± 13.0                                       38                                    31.7                                  49.2                                    N/A                                                                                                                                                                               44.3                         40.6 ± 12.9
  Male                          280 (58.7%)                                595 (64.2%)                        N/A                                   2119 (63.0%)                                      136 (58.9%)                           322 (59.5%)                           90 (71.4%)                              45249 (59.8%)                                                                                                                                                                     1524 (66.7%)                 2084 (59.9%)
  Living donor                  N/A                                        19 (2.0%)                          N/A                                   N/A                                               N/A                                   62 (11.5%)                            41 (32.5%)                              32096 (42.4%)                                                                                                                                                                     80 (3.5%)                    2571 (73.8%)
  HBsAg                         62 (13.0%)                                 37 (4.0%)                          67 (13.2%)                            76 (2.2%)                                         17 (7.3%)                             77 (14.2%)                            63 (50%)                                1346 (1.8%)                                                                                                                                                                       76 (3.3%)                    160 (4.6%)
  HBeAg in HbsAg (+) patients   N/A                                        11/37 (29.7%)                      29/67 (43.3%)                         N/A                                               N/A                                   34/77 (44.2%)                         16/63 (25.4%)                           N/A                                                                                                                                                                               N/A                          N/A
  HBV treatment                 N/A                                        N/A                                Lamivudine 26/67 (39%)                N/A                                               N/A                                   N/A                                   Lamivudine 38/63 (60%)                  N/A                                                                                                                                                                               N/A                          Not specified 129/160 (81%)
  Anti-HCV                      151 (31.7%)                                130 (14.0%)                        0 (0%)                                513 (15.2%)                                       106 (45.9%)                           244 (45.1%)                           0 (0%)                                  0 (0%)                                                                                                                                                                            113 (4.9%)                   55/3482 (1.6%)
  Immunosuppression             Cyclosporine, steroid, azathioprine, MMF   N/A                                Cyclosporine, steroid, azathioprine   Cyclosporine, steroid, azathioprine, MMF, FK506   Cyclosporine, steroid, azathioprine   Cyclosporine, steroid, azathioprine   Cyclosporine/tacrolimus, steroid, MMF   Cyclosporine/tacrolimus, steroid, azathioprine, MMF, mTOR                                                                                                                         N/A                          Cyclosporine/tacrolimus, steroid, azathioprine/MMF
  Follow-up after KTx           6.0 ± 7.0 yr                               9.2 ± 4.4 yr                       82 ± 58 mo                            N/A                                               39.9 (1-10.4.2) mo                    11 yr                                 140.1 mo                                1098 d                                                                                                                                                                            10 yr                        89.1 ± 54.1 mo
  Mortality                     Overall                                    Overall                            No HCV                                Overall                                           Overall                               Overall                               No HCV                                  Overall                                                                                                                                                                           Overall                      2.37 (1.16-4.87)
                                2.72 (1.48-4.99)                           4.08 (2.10-7.93)                   8.07 (3.65-17.86)                     2.06 (1.24-3.40)                                  2.20 (0.57-8.34)                      2.36 (1.50-3.70)                      11.70 (1.45-94.40)                      1.07 (0.88-1.31)                                                                                                                                                                  1.33 (0.78-2.29)             
                                No HCV                                     No HCV                                                                   No HCV                                                                                  No HCV                                                                        Living donor                                                                                                                                                                      No HCV                       
                                4.61 (2.41-8.84)                           3.60 (1.72-7.54)                                                         2.97 (1.66-5.33)                                                                        4.40 (2.06-9.41)                                                              0.98 (0.59-1.63)                                                                                                                                                                  1.02 (0.54-1.94)             
                                                                                                                                                                                                                                                                                                                          Deceased donor                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                          1.09 (0.88-1.36)                                                                                                                                                                                               
  Graft failure                 Overall                                    Overall                            No HCV                                Overall                                           5.45 (1.95-15.23)                     Overall                               N/A                                     Overall                                                                                                                                                                           Overall                      1.38 (0.55-3.50)
                                1.84 (1.08-3.15)                           2.07 (1.06-4.05)                   1.61 (0.86-3.03)                      0.62 (0.37-1.02)                                                                        1.55 (1.12-2.14)                                                              1.02 (0.81-1.28)                                                                                                                                                                  1.57 (0.99-2.49)             
                                No HCV                                     No HCV                                                                   No HCV                                                                                  No HCV                                                                        Living donor                                                                                                                                                                      No HCV                       
                                3.56 (1.89-6.71)                           1.48 (0.71-3.08)                                                         0.59 (0.32-1.09)                                                                        0.65 (0.27-1.54)                                                              0.90 (0.62-1.30)                                                                                                                                                                  1.63 (0.98-2.71)             
                                                                                                                                                                                                                                                                                                                          Deceased donor                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                          1.10 (0.82-1.47)                                                                                                                                                                                               
  Confounder adjustment         None                                       None                               None                                  None                                              None                                  Age, Hepatitis C status               none                                    Recipient age, gender, BMI, race, comorbid, dialysis duration, donor HBcAb, expanded criteria donor, HLA DR mismatch, cold ischemia time, induction therapy, immunosuppressants   none                         Age, sex, DM, BMI, primary renal disease, donor type, hypertension, ischemic heart disease, immunosuppressive agents
  New Castle-Ottawa score       S 4                                        S 4                                S 4                                   S 4                                               S 4                                   S 4                                   S 4                                     S 4                                                                                                                                                                               S 4                          S 4
                                C 0                                        C 0                                C 0                                   C 0                                               C 0                                   C 1                                   C 0                                     C 2                                                                                                                                                                               C 0                          C 2
                                O 3                                        O 3                                O 3                                   O 3                                               O 3                                   O 3                                   O 3                                     O 3                                                                                                                                                                               O 3                          O 3

FK506: Tacrolimus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; HCV: Hepatitis C virus; KTx: Kidney transplantation; MMF: Mycophenolate mofetil; S, C, O: Selection, comparability, and outcome.

Data abstraction
----------------

A structured data collecting form was used to derive the following information from each study including title, year of the study, name of the first author, publication year, country where the study was conducted, demographic and characteristic data, mean age, patient's sex, donor type, % of patients with HBeAg, % of patients with coexist patients infected with hepatitis C virus, and adjusted effect estimates with 95%CI and covariates that were adjusted in the multivariable analysis.

Statistical analysis
--------------------

Comprehensive Meta-analysis (version 3; Biostat Inc) was used to analyze the data. Adjusted point estimates from each study were consolidated by the generic inverse variance approach of DerSimonian and Laird, which designated the weight of each study based on its variance\[[@B49]\]. Given the likelihood of increased inter-observation variance; a random-effect model was utilized to assess the pooled prevalence and pooled OR with 95%CI for the risks of atrial fibrillation with sleep duration, insomnia, and frequent awakening. Cochran's *Q* test and *I*^2^ statistic were applied to determine the between-study heterogeneity. A value of *I*^2^ of 0-25% represents insignificant heterogeneity, 26%-50% represents low heterogeneity, 51%-75% represents moderate heterogeneity, and \> 75% represents high heterogeneity\[[@B50]\]. The presence of publication bias was evaluated *via* the Egger test\[[@B51]\].

RESULTS
=======

A total of 1673 potentially eligible articles were identified using our search strategy. After the exclusion of 1639 articles based on the title and abstract for clearly not fulfilling inclusion criteria on the basis of the type of article, study design, population or outcome of interest, leaving 34 articles for full-length review. Eighteen of them were excluded from the full-length review as they did not report the outcome of interest while six articles were excluded because they were descriptive studies without comparative analysis. Thus, the final analysis included 10 cohort studies\[[@B18],[@B21],[@B31],[@B36],[@B52]-[@B57]\] with 87623 kidney transplant patients. The literature retrieval, review, and selection process are demonstrated in Figure [1](#F1){ref-type="fig"}. The characteristics and quality assessment of the included studies are presented in Table [1](#T1){ref-type="table"}. Patients in most included studies used calcineurin inhibitor-based immunosuppression. Mean age was between the ages of 32-49.

![Literature review process.](WJH-10-337-g001){#F1}

Mortality after kidney transplantation in patients with HBsAg-positive vs HBsAg-negative status
-----------------------------------------------------------------------------------------------

Ten studies assessed the mortality risk after kidney transplantation in patients with HBV as shown in Table [1](#T1){ref-type="table"}. Compared to *HBsAg-negative* patients, HBsAg-positive status was significantly associated with increased risk of mortality after kidney transplantation (pooled OR = 2.48; 95%CI: 1.61-3.83, *I^2^* = 82, Figure [2](#F2){ref-type="fig"}). When meta-analysis was limited only to non-HCV patient population, the pooled OR of mortality was 2.98 (95%CI: 1.47-6.07, *I^2^* = 89). When meta-analysis was limited only to studies with adjusted analysis for confounders\[[@B36],[@B53],[@B54]\], the pooled OR of mortality was 1.27 (95% CI: 1.06-1.51, *I^2^* = 85). Meta-regression showed significant negative correlations between mortality risk after kidney transplantation in HBsAg-positive patients and year of study (slopes = -0.062, *P* = 0.001, Figure [3](#F3){ref-type="fig"}). Meta-regression showed no significant impact of donor type on the association between HBsAg-positive status and increased risk of mortality after kidney transplantation (*P* = 0.11).

![Forest plots of included studies evaluating mortality after kidney transplantation in patients with hepatitis B surface antigen-positive *vs* hepatitis B surface antige -negative.](WJH-10-337-g002){#F2}

![Graphical display of significant negative correlations between mortality risk after kidney transplantation in hepatitis B surface antigen-positive patients and year of study.](WJH-10-337-g003){#F3}

Impact of antiviral treatments on patient survival after kidney transplantation in patients with HBsAg-positive
---------------------------------------------------------------------------------------------------------------

Of 10 studies\[[@B18],[@B21],[@B31],[@B36],[@B52]-[@B57]\], 3 studies\[[@B18],[@B21],[@B54]\] provided data on prophylactic antiviral treatment for HBV. When meta-analysis was limited only to studies with HBsAg-positive recipients (\> 50%) treated with prophylactic antiviral treatment for HBV, the pooled OR of mortality was 3.85 (95%CI: 0.91-16.23, *I*^2^ = 50%). In a recent study by Lee et al\[[@B54]\], which 81% of HBs Ag-positive recipients were treated with prophylactic antiviral treatment, HBsAg-positive status was significantly associated with increased risk of mortality after kidney transplantation with adjusted HR of 2.37 (95%CI: 1.16-4.87).

Yap et al\[[@B18]\] demonstrated that recipients treated with nucleoside/nucleotide analogues had significantly better patient survival, when compared to those who were not on treatment (83% *vs* 34% at 20 years, *P* = 0.006). In patients who had lamivudine-resistant HBV, the investigators showed that treatment with adefovir or entecavir was effective with a three-log reduction in HBV DNA by 6 mo. When compared to patients who were treated with lamivudine or adefovir, Lee et al\[[@B54]\] demonstrated that those treated with new generation antiviral agent entecavir had better patient survival (log-rank, *P* = 0.050).

Renal allograft failure in patients with HBsAg-positive vs HBsAg-negative
-------------------------------------------------------------------------

There were 9 studies assessed renal allograft outcomes in HBsAg-positive patients (Table [1](#T1){ref-type="table"}). HBsAg-positive status was significantly associated with increased risk of renal allograft loss with pooled OR of 1.46 (95%CI: 1.08-1.96, *I^2^* = 69, Figure [4](#F4){ref-type="fig"}). When meta-analysis was limited only to non-HCV patient population, the pooled OR of allograft failure was 1.33 (95%CI: 1.00-1.77, *I^2^* = 80). When meta-analysis was limited only to studies with adjusted analysis for confounders\[[@B36],[@B53],[@B54]\], the pooled OR of allograft failure was 1.25 (95%CI: 0.90-1.73, *I^2^* = 54). There was also a significant negative correlation between year of study and risk of allograft failure (slopes = -0.018, *P* =0.002, Figure [5](#F5){ref-type="fig"}). Meta-regression showed no significant impact of donor type on the association between HBsAg-positive status and increased risk of renal allograft loss (*P* =0.52).

![Forest plots of included studies evaluating renal allograft failure in patients with hepatitis B surface antigen-positive *vs* hepatitis B surface antigen-negative.](WJH-10-337-g004){#F4}

![Graphical display of a significant negative correlation between year of study and risk of allograft failure.](WJH-10-337-g005){#F5}

Evaluation for publication bias
-------------------------------

We found no publication bias as assessed by the funnel plots (Supplementary Figures 1 and 2) and Egger's regression asymmetry test with *P* = 0.18 and 0.13 for the risks of mortality and allograft failure after kidney transplantation in HBV infected patients, respectively.

DISCUSSION
==========

In this systematic review, we demonstrated that HBsAg-positive status in kidney transplant recipients was significantly associated with poor outcomes after transplantation including a 2.5-fold increased risk of mortality and 1.5-fold increased risk of allograft loss. Theses associations existed in overall analysis as well as in limited cohort of hepatitis C virus-negative patients.

Chronic HBV infection can negatively impact the clinical outcomes of kidney allograft recipients. Compared to the HBsAg-negative recipients, HBsAg-positive recipients carry a higher risk of hepatic complications including chronic hepatitis, liver failure, fibrosing cholestatic hepatitis, and hepatocellular carcinoma\[[@B34],[@B36],[@B58]\]. In addition, some immunosuppressive agents after kidney transplantation may also put patients at higher risks of HBV reactivation\[[@B23],[@B40]\]. HBV genome contains glucocorticoid responsive element that activates transcription of HBV genes\[[@B35]\]. Moreover, cyclosporine may also enhance HBV replication, leading to higher risks of HBV-related complications in kidney transplant recipients\[[@B37]\]. Previously, in 2005, Fabrizi et al\[[@B27]\] conducted a meta-analysis of six observational studies and demonstrated a significant association between HBsAg seropositive status and increased mortality after kidney transplantation. Since then, although hepatitis B is still incurable, there have been significant advancements in antiviral agents including the United States Food and Drug Administration approvals of entecavir in 2005 and telbivudine in 2006\[[@B59]\] resulting in reasonably sustained suppression of HBV replication after kidney transplantation\[[@B10]\]. Our meta-analysis with a new era of medicine also demonstrated a 2.7-fold increased risk of mortality in kidney transplant recipients with HBsAg positivity, when compared to HBsAg-negative recipients. In addition, our meta-analysis is the first to demonstrate a significant negative correlation between the mortality risk and year of study, which potentially represents improvements in patient care and management for chronic HBV in kidney transplant patients\[[@B60]\]. Although antiviral treatment has been shown to reduce mortality after kidney transplantation due to decrease in liver complications\[[@B18],[@B21],[@B54]\], in the era of antiviral therapies, Lee et al\[[@B54]\] recently showed that deaths from liver complications remained a significant problem accounting for 40% of deaths in HBsAg patients and 22.2% of all mortalities that occurred in recipients treated with antiviral agents\[[@B54]\].

There are several plausible explanations for the increased risk of renal allograft failure in recipients with HBsAg-positivity. Firstly, it is known that chronic HBV infection can result in HBV-related membranous nephropathy, not only in patients with native kidneys but also in kidney transplant recipients\[[@B37]-[@B43]\]. Secondly, due to a concern of HBV reactivation, physicians may avoid or limit the use particular immunosuppression or Rituximab in HBsAg-positive patients when it is indicated such as for recurrent glomerulonephritis post-transplantation\[[@B61],[@B62]\]. Lastly, treatment of chronic HBV infection itself such as tenofovir could affect renal function\[[@B63]\]. Thus, the findings from our meta-analysis confirm an increased risk of allograft failure in HBsAg seropositive patients, when compared to HBsAg-negative recipients. Also, we found a significant negative correlation between the risk of allograft failure in HBsAg positive patients and year of study. Recently, data analysis from the Organ Procurement Transplant Network/United Network for Organ Sharing database (OPTN/UNOS) suggested no increased risk for allograft failure or death in HBV-infected kidney transplant patients in a recent era (between 2001 and 2007)\[[@B36]\]. Although follow-up time was limited to only 3 years post-transplant, these data along with the findings from our study suggest potential improvements in patient and graft survivals in HBsAg-positive recipients overtime.

There are several limitations in this meta-analysis that bear mentioning. First, there was low to moderate statistical heterogeneity between studies in meta-analysis assessing the risks of mortality and allograft failure in HBsAg-positive recipients. The possible source of this heterogeneity includes the difference in population, type of donor, number of patients with positive HBeAg, immunosuppression regimens, and difference in confounder adjustments. In addition, the data on the graft quality (*e.g*., Kidney Donor Profile Index) and surgical technique in HBsAg-positive recipients were limited. Second, despite the associations of HBsAg-positive status with poor kidney transplant outcomes, there is limited evidence whether the treatment with antiviral drugs for chronic HBV helps improve patient and allograft survival. However, with potential improvements in patient and graft survivals overtime demonstrated in our meta-analysis, future studies are required to evaluate if advancement in patient care for chronic HBV plays an important role. Also, additional studies are required to identify optimal antiviral treatment regimens and duration of suppressive therapy for HBV after kidney transplantation, since outcomes after withdrawal of antiviral treatment in kidney transplant recipients with chronic HBV infection remain unknown. While cautious withdrawal of antiviral therapy post kidney transplantation has been described especially in those with stable renal allograft function, low immunological risk for rejection and no evidence for HBV activity\[[@B10],[@B23]\], fatal hepatitis flares in several kidney transplant recipients have been reported after withdrawal of antiviral therapy\[[@B64]\]. Lastly, this is a meta-analysis of observational studies. Thus, it can at best identify only associations of HBsAg-positive status with poor kidney transplant outcomes, but not a causal relationship.

In summary, our study reveals an association between HBsAg-positive status in kidney transplant recipients and higher risks of mortality and allograft failure after kidney transplantation. However, there are also significant negative correlations between the risks of mortality and allograft failure and year of study, representing potential improvements in patient and graft survivals overtime.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Among renal transplant patients with hepatitis B virus (HBV) (HBsAg positive), there have been reported cases of HBV reactivation, massive liver necrosis due to fulminant hepatitis, and severe cholestatic hepatitis after kidney transplantation. In spite of improvement of HBV care, the outcomes of kidney transplantation including patient and allograft outcomes in recipients with HBV infection remain unclear.

Research motivation
-------------------

Although hepatitis B is still incurable, there have been significant advancements in antiviral agents resulting in reasonably sustained suppression of HBV replication after kidney transplantation. The results of studies on kidney transplant outcomes in patients with renal transplant patients with HBV (HBsAg positive) were inconsistent. To further investigate outcomes of renal transplant patients with HBsAg positivity, the authors conducted this systematic review and meta-analysis reporting the association between HBsAg positivity in kidney transplant recipients and higher risks of mortality and allograft failure after kidney transplantation.

Research objectives
-------------------

We conducted this meta-analysis to assess the outcomes of kidney transplantation including patient and allograft outcomes in recipients with HBV infection; and the trends of patient's outcomes overtime.

Research methods
----------------

A literature search was conducted using databases (MEDLINE, EMBASE and Cochrane Database) from inception through October 2017. Those studies reported odds ratios (OR) of mortality or renal allograft failure after kidney transplantation in HBV patients (defined as HBsAg positive) were included. HBsAg-negative kidney transplant recipients are the comparison group. The effect estimates from the individual study were extracted and combined.

Research results
----------------

The authors demonstrated that HBsAg-positive status in kidney transplant recipients was significantly associated with poor outcomes after transplantation. These associations existed in overall analysis as well as in limited cohort of hepatitis C virus-negative patients.

Research conclusions
--------------------

The authors found significant associations of HBsAg positive status with poor outcomes after transplantation. Significant negative correlations between the risks of mortality and allograft failure and year of study, representing potential improvements in patient and graft survivals overtime were found.

Research perspectives
---------------------

This study demonstrated significantly increased risks of mortality and allograft failure in HBsAg-positive kidney transplant recipients. This finding suggests that HBsAg positive status may be an independent potential risk factor for poor outcomes after transplantation. However, there are also potential improvements in patient and graft survivals with HBV infection overtime.
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